Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer. At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara M. Tolaney sat down for ...

Camizestrant combined with CDK4/6 inhibitors improved progression-free survival in HR+/HER2- advanced breast cancer with ESR1 mutations in the SERENA-6 trial. In the phase 3 SERENA-6 trial ...

首先，在新辅助治疗中，传统观点认为总体病理完全缓解（tpCR）与预后密切相关。然而，我们在临床实践中观察到，部分患者的乳腺达到pCR（bpCR），但腋窝淋巴结未达到pCR；也有一些患者乳腺未达到pCR，但腋窝淋巴结达到pCR。这种现象相对少见，因此我 ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

possibly in combination with trastuzumab antibody-drug conjugates, such as trastuzumab emtansine CDK4/6 inhibitors are a more recent treatment option to prevent cancer cell growth and include the ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Atirmociclib作为一种CDK4选择性抑制剂，与现有的CDK4/6抑制剂哌柏西利相比，其在结构上对CDK4的亲和力更高，选择性更强。 细胞 ...

Antibody-Drug Conjugate Found Effective Against ... hemispheric glioma and discovered an unexpected vulnerability to CDK4/6 ... New Study Uncovers Key Mechanisms Responsible for the Transformation ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...